Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTRA is a good fit for your portfolio.
News
-
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
-
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
-
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
-
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
-
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
-
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
-
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
-
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
Trading Information
- Previous Close Price
- $87.21
- Day Range
- $83.21–87.07
- 52-Week Range
- $36.94–98.76
- Bid/Ask
- $84.92 / $84.98
- Market Cap
- $10.25 Bil
- Volume/Avg
- 1.5 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.27
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,018
- Website
- https://www.natera.com
Comparables
Valuation
|
Metric
|
NTRA
|
GH
|
SLGC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 13.64 | 12.78 | 0.80 |
Price/Sales | 9.27 | 3.31 | 4.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NTRA
|
GH
|
SLGC
|
|---|---|---|---|
Quick Ratio | 3.77 | 6.11 | 17.08 |
Current Ratio | 4.10 | 6.54 | 17.79 |
Interest Coverage | −35.31 | −198.43 | — |
Quick Ratio
NTRA
GH
SLGC
Profitability
|
Metric
|
NTRA
|
GH
|
SLGC
|
|---|---|---|---|
Return on Assets (Normalized) | −20.66% | −20.62% | −18.10% |
Return on Equity (Normalized) | −40.41% | −253.35% | −20.69% |
Return on Invested Capital (Normalized) | −25.54% | −25.20% | −23.76% |
Return on Assets
NTRA
GH
SLGC
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Lyvbczkwx | Kjqz | $208.9 Bil | |
DHR
| Danaher Corp | Nhtdtnnq | Nxmxl | $175.0 Bil | |
IQV
| IQVIA Holdings Inc | Zkvtxnlc | Bvxqlr | $41.3 Bil | |
IDXX
| IDEXX Laboratories Inc | Xycpqwgkvs | Qnfxfh | $39.7 Bil | |
A
| Agilent Technologies Inc | Zdlmgfbp | Sgf | $39.4 Bil | |
MTD
| Mettler-Toledo International Inc | Snlwcgwvcp | Vbxlb | $25.6 Bil | |
ICLR
| Icon PLC | Lwbykskk | Kglwqb | $24.1 Bil | |
ILMN
| Illumina Inc | Skckwdmf | Qrmxl | $18.6 Bil | |
WAT
| Waters Corp | Ytlljmhsm | Vdl | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Hgkqtjdlj | Mzpqd | $16.8 Bil |